In Q1 FY2026 (ended March 31, 2026), Veracyte reported revenue of $139.1 million, up 21.5% year-over-year. Net income was $28.7 million, a 307% increase, and operating income reached $22.6 million, up 680%. Diluted EPS was $0.35, up 289%. The company held $263.1 million in cash and had total equity of $1.34 billion, with no long-term debt.
•Revenue grew 21.5% YoY to $139.1 million.
•Net income surged 307% to $28.7 million.
•Operating income rose 680% to $22.6 million.
•Diluted EPS increased 289% to $0.35.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Veracyte is a diagnostics company in the United States and globally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules. Its portfolio also includes Decipher Prostate Genomic Classifiers for prostate cancer diagnosis, Decipher Bladder Genomic Classifier for bladder cancer diagnosis, Prosigna Breast Cancer Assay for breast cancer diagnosis, and Percepta Nasal Swab Test for lung cancer diagnosis
The nCounter analysis system services. Incorporated in 2006 and headquartered in South San Francisco, California, Veracyte was formerly known as Calderome, Inc. before rebranding in March 2008.
Veracyte, Inc. is a diagnostics company operating in the United States and globally. The company specializes in genomic testing and analysis for cancer diagnosis. Its main products include the Afirma Genomic Sequencing Classifier for evaluating cancerous thyroid nodules, the Decipher Prostate Genomic Classifiers for prostate cancer diagnosis, the Decipher Bladder Genomic Classifier for bladder cancer, the Prosigna Breast Cancer Assay for breast cancer, and the Percepta Nasal Swab Test for lung cancer. Additionally, Veracyte offers nCounter analysis system services. The company's tests help clinicians make more informed decisions about patient care, potentially reducing unnecessary surgeries and improving outcomes.
On which stock exchange is Veracyte (VCYT) listed and in what currency?
Veracyte, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol VCYT. The company's shares are traded in US Dollars (USD). As a US-based company, its financial reporting and stock trading are conducted in the local currency, which is standard for companies listed on US exchanges.
What sector and industry does Veracyte (VCYT) belong to?
Veracyte, Inc. operates in the Healthcare sector, specifically within the Diagnostics & Research industry. This industry focuses on developing and providing diagnostic tests, research tools, and analytical services that aid in disease detection, monitoring, and treatment decisions. As a diagnostics company, Veracyte's work is critical in oncology, offering genomic classifiers and assays that help identify cancer types and guide personalized treatment plans.
Where is Veracyte (VCYT) headquartered and what is its history?
Veracyte, Inc. is headquartered in South San Francisco, California, United States. The company was incorporated in 2006 and was originally known as Calderome, Inc. before rebranding to Veracyte in March 2008. Since its founding, Veracyte has focused on developing genomic-based diagnostic solutions for cancer, with a portfolio that includes tests for thyroid, prostate, bladder, breast, and lung cancers. The company serves both the US and global markets, leveraging its expertise in molecular diagnostics to improve patient outcomes.
What are the main products in Veracyte's (VCYT) portfolio?
Veracyte's product portfolio includes several genomic classifiers and assays for cancer diagnosis. The Afirma Genomic Sequencing Classifier is used for evaluating cancerous thyroid nodules. For prostate cancer, the company offers the Decipher Prostate Genomic Classifiers. The Decipher Bladder Genomic Classifier aids in bladder cancer diagnosis. The Prosigna Breast Cancer Assay is designed for breast cancer diagnosis, and the Percepta Nasal Swab Test is used for lung cancer diagnosis. Additionally, Veracyte provides nCounter analysis system services, which support gene expression analysis. These products are part of the company's effort to provide accurate, non-invasive diagnostic options.